News
Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...
Summary: Maraviroc is the first CCR5 coreceptor antagonist to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of CCR5-tropic human immunodeficiency virus ...
Department of Chemistry, University of Florence, Via della Lastruccia 3, Sesto Fiorentino 50019, Italy Magnetic Resonance Center (CERM), University of Florence, Via Luigi Sacconi 6, Sesto Fiorentino ...
Long working hours might not just be bad for you, they could also be altering the structure of your brain, a new study suggests. The research was conducted by two scientists at South Korea’s ...
Conclusion: The increased expression of CCL5 and CXCL7 in the bronchial mucosa of patients with stable COPD, together with an increased expression of extracellular matrix-binding receptors on ...
consistent with differences in receptor binding affinities. Surprisingly, IL‐17F adopts a cystine knot fold and dimerization mode reminiscent of the neurotrophin family of cystine knot growth factors ...
YTHDC1 depletion in BAT impairs postnatal interscapular BAT development and thermogenesis. YTHDC1 stabilizes master regulator PPARγ, binding it via its intrinsically disordered region and preventing ...
Although many computational methods have been developed for predicting RNA-protein binding sites, few study considers the k-mer embedding representation of RNA primary sequence and secondary structure ...
Platelets are small types of blood cells that prevent excessive bleeding. It’s possible to develop low or high platelet counts related to a number of health conditions. Platelets are one of the ...
Her research group has developed genome editing techniques for human hematopoietic stem cells and is currently developing anti-HIV gene therapy technologies that target the CCR5 gene. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results